Adeza Biomedical Corporation is a medical technology company located in Sunnyvale, California. Adeza’s products are recognized worldwide through both direct sales and distribution in over 20 countries.

Adeza’s product focus is on proprietary tests and services for the diagnosis of pregnancy-related and female reproductive disorders including premature birth and infertility. In the US, preterm birth is the leading cause of perinatal mortality and morbidity with healthcare costs exceeding $12 billion annually.

Adeza received an expedited premarket approval from the US Food and Drug Administration (FDA) to market the proprietary fetal fibronectin (fFN) test. The fFN test detects a protein found in pregnant women and is used to determine the risk of premature birth from 22 to 35 weeks of pregnancy. The fFN test has demonstrated effectiveness in over 125 published peer reviewed studies and is available on Adeza’s TLi_IQ® system. Adeza has shipped over 1,250 TLi_IQ® systems in the US and Canada.

Adeza also offers the services of Adeza Diagnostic Services (ADS), a CLIA-approved and California-licensed reference laboratory.

The E-tegrity® test is a biochemical method for assessing uterine receptivity in cases of unexplained infertility. This test provides an accurate way to determine the feasibility of embryo implantation.

Adeza’s mission is to ensure the healthiest possible, cost-effective outcome for women and their families. In 2003, Adeza was recognized as the 8th fastest growing privately held company in California’s Silicon Valley. Adeza is committed to become a health care leader – providing leading edge technology in medical diagnostics, laboratory services, research and product development.